Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Halle
Clinical trial register · Germany

Clinical Trials in Halle, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 1591 Hamburg 896 Essen 767 Dresden 717 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC13 AstraZeneca10 Novartis Pharmaceuticals9 Merck Sharp & Dohme LLC9 Incyte Corporation8 Eli Lilly and Company8 Bristol-Myers Squibb6 Hoffmann-La Roche5 Takeda5 Jena University Hospital5 AbbVie4 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4 Technische Universität Dresden4 Novo Nordisk A/S4 Regeneron Pharmaceuticals4 Sanofi4 Christian Buske3 Philogen S.p.A.3 Celgene3 GlaxoSmithKline3 Gilead Sciences3 Aesculap AG2 Karyopharm Therapeutics Inc2 Genmab2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS2 Show all 118
Site location
Berlin1591 Hamburg896 Essen767 Dresden717 Heidelberg626 Cologne619 Leipzig515 München513 Hanover488 Tübingen457 Bonn424 Düsseldorf409 Munich398 Freiburg im Breisgau392 Erlangen373 Frankfurt369 Münster359 Frankfurt am Main346 Ulm343 Mainz336 Würzburg299 Aachen267 Augsburg248 Kiel236 Lübeck225 Show all 642
All 642 locations
Target enrolment
to

Trials with a site in Halle

224 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-12-14
Recruiting
Philogen S.p.A.
Phase 2
180
Augsburg, Berlin, Essen, Halle, Kiel, Tübingen
2026-09-28
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Bad Homburg, Bonn, Brandenburg, Dresden, Düsseldorf, Essen, Gütersloh, Halle
2026-09-24
Recruiting
Bristol-Myers Squibb
Phase 2
160
Stuttgart, Marburg, Homburg, Cologne, Halle, Hessen
2026-09-10
Recruiting
Takeda
Phase 3
324
Freiburg im Breisgau, Heidelberg, Mutlangen, Minden, Koblenz, Chemnitz, Halle, Jena
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg
2026-09-08
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Recruiting
NG004 in Incomplete Spinal Cord Injury Patients
NCT07840196Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Spinal Cord Injuries, Trauma Nervous System
DrugNG004
NovaGo Therapeutics AG
Phase 1
120
Bayreuth, Bochum, Halle, Hamburg, Heidelberg, Murnau am Staffelsee, Tübingen
2026-08-05
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
Cologne, Essen, Halle
2026-08-04
Not yet open
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Berlin, Cologne, Essen, Frankfurt am Main, Göttingen, Halle, Hamburg, Heidelberg
2026-07-01
Recruiting
Pharming Technologies B.V.
Phase 2
140
Halle
2026-06-12
Recruiting
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3
320
Berlin, Bonn, Gera, Göttingen, Halle, Karlsruhe, Recklinghausen, Rostock
2026-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Jena, Kassel
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Augsburg, Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Kassel
2026-05-22
Recruiting
Takeda
Phase 3
300
Bayreuth, Münster, Halle, Berlin
2026-05-21
Recruiting
Incyte Corporation
Phase 1
218
Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz
2026-05-11
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Halle, Greifswald, Mainz
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Not yet open
Pea Fibre in Hemodialysis
NCT07544797Hemodialysis, Kidney Failure Chronic
Martin-Luther-Universität Halle-Wittenberg
Not applicable
72
Halle
2026-05-01
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
875
Aachen, Bochum, Bonn, Braunschweig, Greifswald, Halle, Hamburg, Hanover
2026-03-01
Recruiting
Genmab
Phase 2
240
Berlin, Essen, Halle, Heidelberg
2026-01-30
Recruiting
Sanofi
Phase 3
751
Tübingen, Ulm, Leipzig, Halle, Kiel, Berlin, Minden
2026-01-16
Recruiting
AstraZeneca
Phase 1/2
85
Dresden, Frankfurt A. Main, Halle, Heidelberg, München, Ulm
2026-01-09
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
Christian Schulze
Phase 3
536
Jena, Bad Nauheim, Berlin, Bonn, Dresden, Göttingen, Halle, Leipzig
2025-12-08
Recruiting
Bristol-Myers Squibb
Phase 3
650
Düsseldorf, Halle, Westerstede
2025-12-02
Recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
NCT07203768Polycythemia Vera, Thrombocythemia
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
678
Halle, Hanover, Minden
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Frankfurt am Main, Berlin, Cologne, Dresden, Halle, Hamburg
2025-11-30
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Halle, Weilheim, Wuppertal
2025-11-24
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Leipzig, Halle, Jena
2025-11-11
Recruiting
AstraZeneca
Phase 2
435
Berlin, Darmstadt, Essen, Frankfurt, Halle, Hanover, Konstanz, München
2025-11-06
Recruiting
Shionogi
Phase 2
45
Halle, Höchheim, München
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Recruiting
Sanofi
Phase 3
980
Wolfsburg, Halle, Berlin, Herne, Kiel, Leipzig, Minden, Ulm
2025-10-08
Recruiting
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
NCT07181369Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
Granular Therapeutics Limited
Phase 1
72
Berlin, Halle, Marburg, Münster
2025-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig
2025-10-03
Recruiting
Incyte Corporation
Phase 1
120
Dresden, Halle, Mainz
2025-10-01
Recruiting
Sanofi
Phase 3
980
Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Halle
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Aachen, Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2
182
München, Frankfurt am Main, Halle, Cologne, Würzburg
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg
2025-09-08
Recruiting
Periotrap Pharmaceuticals GmbH
Not applicable
28
Halle, Bietigheim-Bissingen, Borna, Straubing
2025-07-28
Recruiting
Bristol-Myers Squibb
Phase 3
426
Düsseldorf, Halle, Westerstede
2025-07-16
Recruiting
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Ahrensburg, Bendorf, Berlin, Darmstadt, Halle, Hanover, Landsberg, Leipzig
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Halle, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bochum, Bramsche, Darmstadt
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Eli Lilly and Company
Phase 3
350
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
290
Frankfurt, Grevenbroich, Halle, Hanover, Leipzig, Potsdam
2025-06-26
Recruiting
GlaxoSmithKline
Phase 3
961
Munich, Fürstenwalde, Darmstadt, Giessen, Offenbach, Rheine, Bendorf, Halle
2025-06-23
Recruiting
Technische Universität Dresden
Phase 2
76
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt am Main, Greifswald, Halle
2025-06-17
Recruiting
Relay Therapeutics, Inc.
Phase 2
277
Halle
2025-06-13
Recruiting
SecuraBio
Phase 3
124
Essen, Goettigen, Halle, Leipzig
2025-05-19
Recruiting
Takeda
Phase 3
225
Bonn, Düsseldorf, Leipzig, Halle, Magdeburg, Berlin
2025-05-06
Recruiting
Brain Signal Training to Enhance Affect Down-regulation
NCT06626789Borderline Personality Disorder
Central Institute of Mental Health, Mannheim
Phase 1/2
164
Freiburg im Breisgau, Giessen, Halle, Hamburg, Mannheim, Tübingen
2025-04-23
Recruiting
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle
2025-03-27
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm
2025-03-17
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Stuttgart, Munich, Herne, Halle, Jena
2025-03-11
Recruiting
BeOne Medicines
Phase 3
300
Chemnitz, Frankfurt am Main, Halle, Mutlangen, München, Siegen, Stuttgart
2025-03-05
Active, closed
POROUS GmbH
Not applicable
1,600
Berlin, Halle, Marburg
2025-03-03
Recruiting
Summit Therapeutics
Phase 3
780
Chemnitz, Esslingen am Neckar, Gauting, Giesen, Halle, Herne, Karlsruhe, Minden
2025-02-27
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3
339
Aachen, Berlin, Cologne, Greifswald, Halle, Rostock, Zwickau
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Frankfurt am Main, Oldenburg, Cologne, Halle, Bad Berka, Gauting, Großhansdorf, Heidelberg
2025-02-25
Recruiting
Hannover Medical School
Not applicable
274
Berlin, Bonn, Braunschweig, Bremerhaven, Cologne, Erlangen, Essen, Halle
2025-02-19
Active, closed
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
NCT07091682Coronary Artery Disease, Atherosclerosis of Coronary Artery, Myocardial Ischemia, Ischemic Heart Disease
Biotronik AG
Not applicable
100
Erfurt, Halle, Immenstadt and Kempten, München
2025-02-18
Recruiting
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
University of L'Aquila
Observational
200
Berlin, Halle
2025-02-12
Recruiting
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Langenau, Darmstadt, Dresden, Halle, Berlin, Bochum, Bonn, Erlangen
2025-01-31
Active, closed
AbbVie
Phase 1
4
Ulm, Halle, Kiel, Berlin, Hamburg
2025-01-27
Recruiting
Colorectal Resections in Patients With Retroperitoneal Sarcoma
NCT06943612Sarcoma, Soft Tissue, Retroperitoneal Sarcoma
Heidelberg University
Observational
120
Mannheim, Göttingen, Berlin, Cologne, Dresden, Erlangen, Greifswald, Halle
2025-01-27
Recruiting
Ascentage Pharma Group Inc.
Phase 3
490
Berlin, Dresden, Düsseldorf, Halle, Leipzig, Stuttgart, Ulm
2025-01-22
Recruiting
Incyte Corporation
Phase 3
240
Aachen, Berlin, Bonn, Dresden, Düsseldorf, Erlangen, Essen, Halle
2025-01-21
Recruiting
Takeda
Phase 3
396
Berlin, Frankfurt am Main, Halle, Jena, Kiel, Ludwigshafen, Mannheim
2025-01-02
Recruiting
Early Catheter-directed Treatment of High Risk Pulmonary Embolism
NCT06672081Pulmonary Embolism Acute Massive
Leipzig Heart Science gGmbH
Not applicable
210
Bad Krozingen, Bautzen, Bonn, Düsseldorf, Erfurt, Frankfurt am Main, Halle, Hamburg
2024-12-27
Active, closed
NG004 in Spinal Cord Injury Patients
NCT06817577Acute Spinal Cord Injury (SCI), Spinal Cord Diseases, Central Nervous System Diseases, Nervous System Diseases
DrugNG004
NovaGo Therapeutics AG
Phase 1
20
Bayreuth, Halle, Heidelberg, Murnau am Staffelsee
2024-12-18
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Recruiting
CUTISS AG
Phase 3
70
Berlin, Halle, Hanover, Murnau am Staffelsee
2024-12-13
Active, closed
Genmab
Phase 3
191
Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf
2024-11-25
Recruiting
AWOgyn
Observational
135
Weinheim, München, Frankfurt am Main, Wesel, Halle
2024-11-08
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Heidelberg, München, Dresden, Halle
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Recruiting
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Observational
617
Halle, Hanover, Minden
2024-10-14
Active, closed
Ipsen
Observational
424
Berlin, Frankfurt, Halle, Herne, Homburg, Leipzig
2024-10-14
Recruiting
Enhancing Palliative Care in ICU
NCT06605079Palliative Care
Charite University, Berlin, Germany
Not applicable
2,040
Mitte, Wedding, Berlin, Düsseldorf, Halle, Neuss, Wittenberg
2024-10-10
Active, closed
Eli Lilly and Company
Phase 2
143
Augsburg, Berlin, Brandenburg an der Havel, Duisburg, Frankfurt am Main, Halle, Hamburg, Hanover
2024-10-10
Active, closed
Incyte Corporation
Phase 3
349
Aachen, Bad Bentheim, Berlin, Dortmund, Halle, Hamburg, Heidelberg, Leipzig
2024-10-10
Active, closed
Nocion Therapeutics
Phase 2
455
Munich, Darmstadt, Frankfurt am Main, Marburg, Halle, Geesthacht, Lübeck, Berlin
2024-09-24
Recruiting
Prospective WCD Post CABG Registry (CABG Registry)
NCT06570902Cardiomyopathy Ischemic, Cardiomyopathies, Cardiovascular Diseases, Heart Disease, Ischemic
Zoll Medical Corporation
Observational
910
Bad Nauheim, Hanover, Cottbus, Halle
2024-09-23
Active, closed
Sanofi
Phase 2
229
Berlin, Halle, Mainz
2024-08-29
Active, closed
Incyte Corporation
Phase 1
37
Aachen, Essen, Halle
2024-08-08
Recruiting
NovoCure GmbH
Phase 3
734
Berlin, Giessen, Halle, Heidelberg, Löwenstein, Oldenburg
2024-07-31
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Berlin, Dachau, Duisburg, Frankfurt am Main, Halle, Heidelberg, Kiel, Leipzig
2024-07-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin
2024-07-16
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Observational
4,000
Aachen, Greifswald, Halle, Rostock
2024-06-28
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Augsburg, Bielefeld, Chemnitz, Frankfurt, Freiburg im Breisgau, Halle, Hamburg, Kiel
2024-06-26
Active, closed
Celgene
Phase 3
850
Ulm, Augsburg, Bayreuth, Erlangen, Langen, Hanover, Koblenz, Halle
2024-06-19
Active, closed
Novartis Pharmaceuticals
Observational
116
Hamburg, Lingen, Koblenz, Leipzig, Halle, Ahaus, Berlin, Bremen
2024-06-11
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel
2024-06-03
Recruiting
Long-term Follow-up of Children Born in the PETN Studies
NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children
Jena University Hospital
Observational
228
Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle
2024-06-01
Recruiting
A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial
NCT04183660Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure
Hemovent GmbH
Observational
60
Hanover, Essen, Halle, Erfurt
2024-04-30
Recruiting
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
NCT05717192Emphysema or Chronic Obstructive Pulmonary Disease
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
224
Berlin, Bonn, Essen, Halle, Heidelberg, Hemer, Immenhausen, Langen
2024-04-24
Active, closed
Janssen-Cilag Ltd.
Phase 3
120
Augsburg, Berlin, Dachau, Frankfurt, Göttingen, Halle, Hanover, Kiel
2024-04-17
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Halle, Kiel, Münster, Stuttgart
2024-04-15
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Cologne, Halle, Leverkusen, Lübeck, Mettmann, München
2024-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Esslingen am Neckar, Regensburg, Hemer, Koblenz, Leipzig, Halle, Bad Berka, Gera
2024-04-03
Not yet open
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
NCT05587621ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
Jena University Hospital
Not applicable
300
Jena, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg
2024-04-01
Recruiting
Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data
NCT06317181Artificial Intelligence, Ultrasonography, Elasticity Imaging Techniques, Liver Diseases
Technische Universität Dresden
Not applicable
200
Dresden, Halle, Leipzig
2024-04-01
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
Munich, Regensburg, Dresden, Halle, Berlin
2024-03-28
Recruiting
Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2
NCT06025123Out-Of-Hospital Cardiac Arrest, Hypothermia, Ventricular Fibrillation
Karolinska Institutet
Not applicable
1,022
Bamberg, Freiburg im Breisgau, Halle, Kandel
2024-03-27
Active, closed
Gilead Sciences
Phase 2
228
Dresden, Halle, Kiel, Ulm
2024-03-27
Recruiting
Italfarmaco
Phase 3
220
Mannheim, Dresden, Halle, Hamburg
2024-03-26
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Düsseldorf, Halle, Moers, Neuss
2024-03-12
Active, closed
Real World Use of Tocilizumab Biosimilar studY
NCT06247722Rheumatoid Arthritis
Fresenius Kabi SwissBioSim GmbH
Observational
600
Berlin, Halle, Ludwigsfelde, Magdeburg, Naumburg, Planegg, Potsdam, Templin
2024-03-05
Recruiting
Pulmonx Corporation
Not applicable
200
Essen, Halle, Hamburg, Heidelberg, Hemer
2024-02-22
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Halle, Bonn, Esslingen am Neckar, Frankfurt a.M., Gauting, Großhansdorf, Heidelberg
2024-02-21
Active, closed
AbbVie
Observational
427
Wolfach, Munich, Potsdam, Osnabrück, Halle, Beelitz-Heilstätten, Bottrop
2024-01-24
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg
2024-01-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Aachen, Dresden, Halle
2023-12-31
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Mutlangen, Stuttgart, Munich, Frankfurt am Main, Essen, Mainz, Halle, Kiel
2023-12-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Ulm, Landshut, Mönchengladbach, Koblenz, Halle, Berlin
2023-12-13
Active, closed
AOP Orphan Pharmaceuticals AG
Phase 3
117
Aachen, Halle, Hanover, Mannheim, Minden, Ulm
2023-12-04
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Freiburg im Breisgau, Munich, Hamburg, Göttingen, Stade, Dresden, Leipzig, Halle
2023-11-15
Active, closed
Acrotech Biopharma Inc.
Phase 3
504
Göttingen, Halle
2023-10-04
By invitation
Biogen
Phase 3
306
Erlangen, Bad Bentheim, Oldenburg, Münster, Dresden, Halle, Berlin
2023-10-03
Active, closed
Incyte Corporation
Phase 1
160
Aachen, Halle, Ulm
2023-09-25
Recruiting
Jena University Hospital
Observational
100
Freiburg im Breisgau, Ulm, Münster, Halle, Jena
2023-09-05
Recruiting
GlaxoSmithKline
Phase 3
892
Berlin, Düsseldorf, Frankfurt, Halle, Lübeck, Mannheim, München
2023-08-01
Active, closed
Novo Nordisk A/S
Phase 3
212
Halle, Hanover, Leipzig, Ulm
2023-07-07
Recruiting
Universität des Saarlandes
Phase 3
330
Homburg, Aschaffenburg, Berlin, Dresden, Giessen, Greifswald, Halle, Karlsruhe
2023-06-07
Active, closed
Jena University Hospital
Phase 3
250
Heidelberg, Wetzlar, Hanover, Planegg, Duisburg, Paderborn, Würselen, Halle
2023-05-16
Recruiting
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Omeros Corporation
Phase 2
18
Halle, Hanover
2023-05-01
Active, closed
IMPACT EU Post-Market Clinical Follow-Up Study
NCT05756751Left Ventricular Dysfunction
Abiomed Inc.
Not applicable
123
Heidelberg, Aachen, Düsseldorf, Essen, Mainz, Halle, Kiel, Berlin
2023-04-27
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
München, Frankfurt, Giessen, Halle, Kempten
2023-04-21
Active, closed
Hoffmann-La Roche
Phase 2
204
Halle, Hamburg
2023-04-13
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
125
Magdeburg, Berlin, Bochum, Chemnitz, Düsseldorf, Erlangen, Essen, Halle
2023-03-20
Recruiting
University of Leipzig
Phase 4
258
Aachen, Augsburg, Berlin, Bonn, Frankfurt, Freiburg im Breisgau, Greifswald, Halle
2023-02-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Mannheim, Kempten (Allgäu), Würzburg, Koblenz, Halle, Berlin
2023-02-06
By invitation
Novo Nordisk A/S
Observational
400
Aachen, Frankfurt am Main, Halle, Mainz, München, Oldenburg, Würzburg
2023-02-03
Active, closed
Invibio Ltd
Observational
24
Halle
2023-02-03
Active, closed
Registry on Percutaneous Electrochemotherapy
NCT05267080Primary Liver Cancer, Secondary Liver Cancer
Cardiovascular and Interventional Radiological Society of Europe
Observational
250
Bonn, Braunschweig, Halle, Leipzig, Regensburg
2023-01-25
Recruiting
Acandis GmbH
Observational
153
Aschaffenburg, Augsburg, Bonn, Bremerhaven, Dresden, Duisburg, Erfurt, Halle
2023-01-25
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Augsburg, Berlin, Bonn, Dortmund, Dresden, Erlangen, Giessen, Halle
2022-12-15
Recruiting
Pharming Technologies B.V.
Phase 2
180
Berlin, Halle
2022-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Munich, Marburg, Bramsche, Göttingen, Merzig, Dresden, Leipzig, Halle
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Kempten (Allgäu), Halle, Hamburg, Oldenburg, Tübingen
2022-12-06
Recruiting
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
NCT05346393Cirrhosis, Liver, Hepatorenal Syndrome, Acute Kidney Injury, Ascites Hepatic
Jena University Hospital
Not applicable
124
Aachen, Berlin, Dresden, Essen, Freiburg im Breisgau, Halle, Hamburg, Hanover
2022-11-29
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Active, closed
University Medical Center Groningen
Phase 3
1,750
Berlin, Düsseldorf, Erlangen, Halle, Hamburg, Hanover, Heidelberg, Heilbronn
2022-11-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Berlin, Essen, Halle, Hamburg, Nuremberg, Tübingen, Würzburg
2022-10-25
Active, closed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Berlin, Bochum, Halle, Hanover, Leipzig, Potsdam
2022-09-23
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Berlin, Dresden, Erlangen, Frankfurt, Frankfurt am Main, Freiburg im Breisgau, Fulda, Halle
2022-09-19
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 2
256
Muenchen, Halle, Essen, Frankfurt, Mönchengladbach, Münster, Tübingen
2022-08-17
Recruiting
Artcline GmbH
Phase 2
142
Freiburg im Breisgau, Regensburg, Bonn, Cologne, Aue, Leipzig, Halle, Kiel
2022-07-24
Recruiting
Priothera SAS
Phase 3
366
Freiburg im Breisgau, Halle, Jena, Leipzig, Munich
2022-06-16
Recruiting
Telios Pharma, Inc.
Phase 1/2
70
Düsseldorf, Halle
2022-06-09
Active, closed
Gilead Sciences
Phase 2
193
Berlin, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Halle
2022-05-30
Active, closed
IO Biotech
Phase 3
407
Augsburg, Berlin, Bochum, Erlangen, Essen, Frankfurt, Halle, Hamburg
2022-05-17
Active, closed
Amgen
Phase 1/2
329
Halle, Heidelberg, Ulm, Würzburg
2022-02-01
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Berlin, Braunschweig, Cologne, Dachau, Duisburg, Halle, Hanover, Jerichow
2022-01-19
Active, closed
Technische Universität Dresden
Phase 2
67
Berlin, Cologne, Dresden, Frankfurt am Main, Gauting, Großhansdorf, Halle, Heidelberg
2022-01-18
Active, closed
Abivax S.A.
Phase 2
203
Frankfurt, Halle, Hanover
2021-12-03
Active, closed
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Active, closed
Hoffmann-La Roche
Phase 3
478
Berlin, Dresden, Halle, Heidelberg, Regensburg, Rostock, Ulm
2021-10-27
Active, closed
Boehringer Ingelheim
Phase 1
151
Freiburg im Breisgau, Halle, Stuttgart
2021-10-18
Active, closed
Study of Lacutamab in Peripheral T-cell Lymphoma
NCT04984837Peripheral T Cell Lymphoma, Relapse/Recurrence
DrugsOxaliplatine·Gemcitabine
The Lymphoma Academic Research Organisation
Phase 2
49
Berlin, Goettigen, Halle, Leipzig, Regensburg
2021-10-05
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Amberg, Bayreuth, Berlin, Cologne, Düsseldorf, Erfurt, Frankfurt, Halle
2021-08-25
Recruiting
Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical
NCT05296889Spine Fracture, Degenerative Disc Disease, Spinal Instability, Spinal Tumor
Aesculap AG
Observational
200
Hamburg, Meppen, Dresden, Halle
2021-07-21
Recruiting
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
NCT04927156Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
Balt Extrusion
Observational
10,000
Halle
2021-07-12
Active, closed
Daiichi Sankyo
Phase 2
155
Halle
2021-06-03
Recruiting
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
NCT05337631HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer
University Hospital Freiburg
Observational
1,500
Berlin, Erlangen, Frankfurt, Giessen, Halle, Jena, Kiel, Leipzig
2021-06-01
Active, closed
Incyte Corporation
Phase 3
899
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Cottbus, Göttingen, Halle
2021-05-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle
2021-04-21
Active, closed
Geron Corporation
Phase 3
327
Mannheim, Tübingen, Dresden, Leipzig, Halle
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Active, closed
Bristol-Myers Squibb
Phase 1/2
216
Erding, Essen, Chemnitz, Halle, Lübeck
2021-03-22
Recruiting
Maastricht University Medical Center
Observational
350
Aachen, Saarbrücken, Halle
2021-03-16
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Mutlangen, Düsseldorf, Halle, Kiel, Jena
2021-03-11
Active, closed
BioNTech SE
Phase 2
327
Berlin, Bochum, Bonn, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg
2021-03-08
Active, closed
Celgene
Phase 3
313
Aachen, Baden-Warttemberg, Düsseldorf, Halle, Hamburg, Jena, Leipzig, Mannheim
2021-02-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Freiburg im Breisgau, Heidelberg, Nuremberg, Frankfurt am Main, Aachen, Homburg/ Saar, Halle, Erfurt
2021-02-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Bad Berka, Bonn, Cologne, Essen, Gauting, Giessen, Grohansdorf, Halle
2021-02-23
Recruiting
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04447352Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCalciumfolinat·Leucovorin·Adrucil·Docetaxel
Krankenhaus Nordwest
Phase 3
200
Aachen, Dresden, Frankfurt, Halle, Leipzig, Ludwigsburg, Lübeck, Magdeburg
2020-12-17
Active, closed
AstraZeneca
Phase 3
358
Berlin, Bielefeld, Cologne, Esslingen a.N., Freiburg im Breisgau, Gauting, Georgsmarienhütte, Halle
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bad Berka, Berlin, Cologne, Essen, Gauting, Halle, Heidelberg, Heilbronn
2020-09-30
Recruiting
Technische Universität Dresden
Phase 1/2
214
München, Essen, Aachen, Augsburg, Chemnitz, Dresden, Frankfurt am Main, Halle
2020-09-04
Recruiting
Takeda
Phase 2
210
Bayreuth, Berlin, Bonn, Düsseldorf, Esslingen am Neckar, Halle, Leipzig, Mainz
2020-08-19
Recruiting
Acotec DCB Post Market Clinical Follow-up
NCT04393389Peripheral Artery Disease
Acotec Scientific Co., Ltd
Observational
3,000
Halle, Eilenburg, Leipzig, Radebeul, Riesa, Sonneberg, Torgau
2020-06-04
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Freiburg im Breisgau, Heidelberg, Braunschweig, Halle
2020-05-21
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Halle, Lübeck
2019-12-16
Active, closed
Christian Buske
Phase 2
36
Bochum, Bonn, Dingolfing, Goch, Goslar, Halle, Kassel, Landshut
2019-12-15
Active, closed
RhoVac APS
Phase 2
180
Dresden, Duisburg, Hagenow, Halle, Nürtingen, Tübingen
2019-11-19
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Mutlangen, Halle, Würzburg
2019-11-13
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
50
Dresden, Essen, Halle, Hanover, Jena, Munich
2019-11-01
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Berlin, Halle, Hanover, Jerichow, Lüneburg, Saarbrücken, Ulm
2019-09-26
Active, closed
Christian Buske
Phase 2
53
Bielefeld, Bremen, Halle, Mannheim, Mönchengladbach, Mutlangen, München, Münster
2019-09-11
Active, closed
Janssen Research & Development, LLC
Phase 1
701
Berlin, Cologne, Essen, Frankfurt am Main, Gauting, Halle, Hemer, Oldenburg
2019-09-04
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz
2019-08-12
Active, closed
AstraZeneca
Phase 3
724
Dresden, Göttingen, Halle, Hanover, Heidelberg, Homburg, Regensburg, Trier
2019-03-06
Active, closed
University Hospital, Montpellier
Phase 2/3
113
Halle
2019-02-18
Active, closed
Obinutuzumab in Marginal Zone Lymphoma
NCT03322865Marginal Zone Lymphoma
DrugObinutuzumab
Christian Buske
Phase 2
56
Bochum, Essen, Freiburg im Breisgau, Göttingen, Halle, Koblenz, Mainz, Mannheim
2018-11-23
Active, closed
AbbVie
Phase 2
270
Mannheim, Augsburg, Giessen, Kassel, Oldenburg, Halle, Berlin, Gauting
2018-10-10
Active, closed
Eli Lilly and Company
Phase 3
1,058
Berlin, Brandenburg, Halle, Hamburg, Hanover, Ludwigshafen
2018-07-18
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Munich, München, Mainz, Dresden, Leipzig, Halle, Magdeburg, Berlin
2018-06-21
Active, closed
GlaxoSmithKline
Phase 2
237
Aachen, Cologne, Dresden, Halle, Leipzig, Lübeck, Mainz
2018-05-03
Recruiting
Post-Market BTVA Registry
NCT03318406Emphysema or COPD
Uptake Medical Technology, Inc.
Observational
300
Bamberg, Berlin, Essen, Gauting, Halle, Heidelberg, Hemer, Immenhausen
2018-03-22
Active, closed
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
112
Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm
2017-11-27
Active, closed
MedSIR
Phase 2
377
Essen, Halle, Heidelberg, Leipzig, Munich, München
2017-06-26
Active, closed
AbbVie
Phase 3
443
Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover
2017-02-02
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 2
87
Aachen, Berlin, Bonn, Düsseldorf, Halle, Hamburg, Jena, Mainz
2016-12-21
Active, closed
Janssen Biotech, Inc.
Observational
535
Berlin, Dessau Roblau, Halle, Hamburg, Heidelberg, Kiel, Leipzig, Ludwigshafen
2016-12-16
Active, closed
AstraZeneca
Phase 3
682
Aachen, Berlin, Cologne, Coswig, Gauting, Gerlingen, Großhansdorf, Halle
2015-10-21
Active, closed
Eli Lilly and Company
Phase 3
545
Gerlingen, Heidelberg, Cologne, Chemnitz, Halle, Großhansdorf, Berlin
2015-05-06
Active, closed
Helmholtz Centre for Infection Research
Observational
782
Braunschweig, Halle
2015-03
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Aachen, Bad Saarow, Berlin, Bremen, Cologne, Dresden, Halle, Hanover
2014-11
Active, closed
AstraZeneca
Phase 3
510
Augsburg, Bad Berka, Cologne, Dortmund, Gerlingen, Großhansdorf, Halle, Heidelberg
2013-09-25
Active, closed
Longterm-Evaluation of Vitelene® Against Standard
NCT01713062Osteoarthritis, Hip, Arthritis
Aesculap AG
Observational
400
Bendorf, Bochum, Halle, Hanover, Mülheim, Olsberg
2012-01
Recruiting
Global Registry and Natural History Study for Mitochondrial Disorders
NCT05554835Mitochondrial Diseases, Kearns-Sayre Syndrome, MIDD, SANDO
LMU Klinikum
Observational
6,000
Munich, Berlin, Bonn, Cologne, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Halle
2009-02-01
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Berlin, Bochum, Bonn, Freiburg im Breisgau, Giessen, Halle, Hamburg, Mainz
2004-09-15
Rows per page Showing 1–224 of 224
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-germany/city/halle

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 224 of those studies with a site in Halle.

How many clinical trials are recruiting in Halle?

119 of the 224 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 98 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Halle), 224 studies
PhaseStudiesRecruitingShare
Phase 3954942.4%
Phase 2542424.1%
Observational332214.7%
Not applicable1596.7%
Phase 1/21174.9%
Phase 11044.5%
Phase 2/3532.2%
Phase 4110.4%

Most active sponsors

Lead sponsors with the most studies (Halle)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC135
AstraZeneca106
Merck Sharp & Dohme LLC93
Novartis Pharmaceuticals92
Eli Lilly and Company85
Incyte Corporation84
Bristol-Myers Squibb65
Hoffmann-La Roche52
Jena University Hospital53
Takeda55
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.